Clinical trial
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial…
NCT00132067 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00132067 |
|---|---|
| Title | Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer |
| Official title | A Phase II Evaluation of Vorinostat, (SAHA, NCI-Supplied Agent [NSC #701852]) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer |
| Intervention type | Drug |
| Interventions | vorinostat |
| Enrollment | 60 |
| Start date | Oct 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Jul 1, 2008 |
| First posted | Aug 19, 2005 |
| Last update posted | Jul 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: